Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2626 AL 2640

Virtual care for patients with Alzheimer disease and related dementias during the COVID-19 era and beyond

Gosse PJ, Kassardjian CD, Masellis M, Mitchell SB.

CMAJ. 2021 Mar 15;193(11):E371-E377. doi: 10.1503/cmaj.201938.

Physical Exercise and Alzheimer's Disease: Effects on Pathophysiological Molecular Pathways of the Disease

López-Ortiz S, Pinto-Fraga J, Valenzuela PL, Martín-Hernández J, Seisdedos MM, García-López O, Toschi N, Di Giuliano F, Garaci F, Mercuri NB, Nisticò R, Emanuele E, Lista S, Lucia A, Santos-Lozano A.

Int J Mol Sci. 2021 Mar 12;22(6):2897. doi: 10.3390/ijms22062897.

A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody

Swanson CJ, Zhang Y, Dhadda S, Wang J, Kaplow J, Lai RYK, Lannfelt L, Bradley H, Rabe M, Koyama A, Reyderman L, Berry DA, Berry S, Gordon R, Kramer LD, Cummings JL.

Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.

Prospects of Saffron and its Derivatives in Alzheimer's Disease

Zandi N, Pazoki B, Momeni Roudsari N, Lashgari NA, Jamshidi V, Momtaz S, Abdolghaffari AH, Akhondzadeh S.

Arch Iran Med. 2021 Mar 1;24(3):233-252. doi: 10.34172/aim.2021.35.

The Effects of Long-term Medication Use in Alzheimer Disease

Karceski S.

Neurology. 2021 Apr 27;96(17):e2247-e2250. doi: 10.1212/WNL.0000000000011843.

Interventional Study to Evaluate the Clinical Effects and Safety of the Nutraceutical Compound BrainUp-10® in a Cohort of Patients with Alzheimer's Disease: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial

Guzman-Martinez L, Farías GA, Tapia JP, Sánchez MP, Fuentes P, Gloger S, Maccioni RB.

J Alzheimers Dis. 2021;81(3):1231-1241. doi: 10.3233/JAD-201501.

Leveraging hallmark Alzheimer's molecular targets using phytoconstituents: Current perspective and emerging trends

Dhage PA, Sharbidre AA, Dakua SP, Balakrishnan S.

Biomed Pharmacother. 2021 Jul;139:111634. doi: 10.1016/j.biopha.2021.111634. Epub 2021 May 6.

Safety and Tolerability of GRF6019 Infusions in Severe Alzheimer's Disease: A Phase II Double-Blind Placebo-Controlled Trial

Hannestad J, Duclos T, Chao W, Koborsi K, Klutzaritz V, Beck B, Patel AK, Scott J, Thein SG, Cummings JL, Kay G, Braithwaite S, Nikolich K.

J Alzheimers Dis. 2021;81(4):1649-1662. doi: 10.3233/JAD-210011.

Does the application of acetylcholinesterase inhibitors in the treatment of Alzheimer's disease lead to depression?

Mitić M, Lazarević-Pašti T.

Expert Opin Drug Metab Toxicol. 2021 Jul;17(7):841-856. doi: 10.1080/17425255.2021.1931681. Epub 2021 Jun 10.

New IDEAS Amyloid Imaging 2021 Study: Running in Place with Ineffective Anti-Amyloid Treatments for Alzheimer's Disease Patients

Barrio JR, Whitehouse P, Alavi A, Høilund-Carlsen PF.

J Alzheimers Dis. 2021;82(2):461-462. doi: 10.3233/JAD-210383.

Benefits in Alzheimer's Disease of Sensory and Multisensory Stimulation

Yang H, Luo Y, Hu Q, Tian X, Wen H.

J Alzheimers Dis. 2021;82(2):463-484. doi: 10.3233/JAD-201554.

The need to show minimum clinically important differences in Alzheimer's disease trials

Liu KY, Schneider LS, Howard R.

Lancet Psychiatry. 2021 Nov;8(11):1013-1016. doi: 10.1016/S2215-0366(21)00197-8. Epub 2021 Jun 1.

Older Adults with Alzheimer's Disease: The Need to Improve Systems of Care

Hung WW.

Clin Ther. 2021 Jun;43(6):920-921. doi: 10.1016/j.clinthera.2021.05.007. Epub 2021 Jun 6.

Effect of Age on Clinical Trial Outcome in Participants with Probable Alzheimer's Disease

Targum SD, Fosdick L, Drake KE, Rosenberg PB, Burke AD, Wolk DA, Foote KD, Asaad WF, Sabbagh M, Smith GS, Lozano AM, Lyketsos CG.

J Alzheimers Dis. 2021;82(3):1243-1257. doi: 10.3233/JAD-210530.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias